Best Kidney Cancer Doctors Abroad for Australian Patients

Professor Bulent Karagoz is a leading oncologist at Anadolu Medical Center, specialising in tumor immunology and targeted therapies for kidney cancer.

• Focuses on immunotherapy – using the body's immune system to recognise and attack cancer cells
• Manages complex renal cell carcinoma (RCC) cases involving vein invasion and advanced spread
• Published over 40 research papers on tumor biology and medical oncology outcomes
• Former Head of Medical Oncology at GATA Haydarpasa Training Hospital
• Member of the Turkish Medical Oncology Association and European Head and Neck Society

The doctor is a highly regarded oncologist at the Anadolu Medical Center, specializing in medical oncology and chemotherapy. After obtaining a medical degree from Ankara University in 2005, the doctor completed specialty training in internal medicine at Istanbul University and further specialized in medical oncology at Marmara University by 2017. The doctor has led the medical oncology unit at Haydarpaşa Numune Training and Research Hospital and has participated in numerous international clinical studies. The doctor focuses on a wide range of cancers, including breast, urological, lung, and gastrointestinal cancers, among others.

The doctor is a member of several prestigious oncology societies, including the Turkish Society of Medical Oncology, the European Society of Medical Oncology, and the American Society of Medical Oncology. The doctor has participated in advanced training programs globally, including programs at Oxford University and ESMO.

The doctor graduated from the School of Medicine at Hacettepe University and completed residency at Istanbul Sisli Etfal Training and Research Hospital, followed by a fellowship at the Hacettepe University Cancer Institute.

Specializing in oncology, the doctor has extensive experience in treating various cancers, including breast, testicular, ovarian, lung, head and neck, and gastrointestinal cancers.

The doctor has worked at prestigious institutions such as The University of Texas MD Anderson Cancer Center, Hitit University Corum Training Hospital, and Medical Park Hospital.

Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.

Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.

Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.

Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.

Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.

Dr Sanbua is a skilled medical radiation oncologist at Panacee Hospital who focuses on managing kidney cancer through integrative and targeted therapies.

• Specialises in oncothermia treatment – uses heat-based therapy to help destroy cancer cells and boost treatment effectiveness
• Expert in IMRT and VMAT – high-precision radiation techniques that target tumours while protecting healthy surrounding tissue
• Provides targeted drug therapy and immunotherapy to help the body's immune system fight kidney cancer tumours
• Trained in palliative care at the Karunrak Center to manage symptoms and improve quality of life

Personal Information 

Sex:  Male

Born : 1968 

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Associate Professor Hasan Mutlu leads medical oncology at Medical Park Antalya, focusing on systemic treatments for organ-based malignancies. He specialises in matching patients with targeted therapies and immunotherapy based on modern genetic mapping.

• Uses targeted cancer therapies to attack specific cancer cells while sparing healthy tissue
• Applies immunotherapy to help the immune system identify and destroy tumours
• Specialises in next-generation genetic research for personalised treatment selection
• Trained as an Associate Professor at Akdeniz University's Department of Medical Oncology
• Integrates complementary medicine to support wellbeing during clinical cancer treatment